Sage Therapeutics (NASDAQ: SAGE)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-02 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.040 | -2.070 | -0.0300 | ||||
REV | 3.210M | 1.582M | -1.628M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Zentalis Pharmaceuticals (NASDAQ:ZNTL), Fate Therapeutics (NASDAQ:FATE), Xencor (NASDAQ:XNCR) and ChemoCentryx (NASDAQ:CCXI).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by Goldman Sachs on Tuesday, May 24, 2022. The analyst firm set a price target for 73.00 expecting SAGE to rise to within 12 months (a possible 126.15% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $32.28 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Sage Therapeutics.
Sage Therapeutics’s Q2 earnings are confirmed for Tuesday, August 2, 2022.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.